Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

BACKGROUND: The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2–4 billion do...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kevin, Zilbermintz, Leeor, Martchenko, Mikhail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462072/
https://www.ncbi.nlm.nih.gov/pubmed/26054754
http://dx.doi.org/10.1186/s12941-015-0090-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462072/
https://www.ncbi.nlm.nih.gov/pubmed/26054754
http://dx.doi.org/10.1186/s12941-015-0090-4

Ejemplares similares